Study: The role of Chromium III in the organism and its possible use in diabetes and obesity treatment
What the article was about
This article is a scientific review examining the role of trivalent chromium (Cr III) in the human body and its possible relevance in diabetes and obesity.
The focus of the article is on chromium’s involvement in metabolic processes and the extent to which supplementation has been studied in experimental models and human populations.
How the article did it
The authors analysed and discussed findings from previously published studies.
The review draws on:
- Human studies including clinical trials and observational research
- Biochemical and physiological studies investigating chromium metabolism and insulin action
The authors compare findings across studies and discuss proposed biological mechanisms, as well as inconsistencies in the evidence.
What the article reports
Based on the reviewed literature, the article reports the following.
Chromium as a nutrient:
- Chromium occurs in several oxidation states, with trivalent chromium being the biologically relevant form in humans.
- Trivalent chromium is described as being involved in carbohydrate, lipid, and protein metabolism.
- Early research identified chromium as a component of the glucose tolerance factor, which was proposed to enhance insulin action.
Findings from experimental and human studies:
- Some human studies in individuals with diabetes have reported improvements in glucose control and insulin sensitivity following chromium supplementation.
- Chromium is suggested to enhance insulin signalling through interactions with insulin receptors and intracellular proteins such as chromodulin.
What it means according to the article
The authors conclude that trivalent chromium plays a role in metabolic processes related to glucose and lipid metabolism.
Study: The effects of chromium supplementation on lipid profile in humans: A systematic review and meta-analysis of randomised controlled trials
What the study was about
A randomised controlled trial that examined the effects of chromium supplementation on blood lipid levels. The aim was to assess whether chromium has measurable effects on lipid markers commonly used to assess cardiovascular risk.
The lipid markers assessed included:
- Total cholesterol
- Triglycerides
- Low density lipoprotein cholesterol
- Very low-density lipoprotein cholesterol
How the study was conducted
The authors carried out a systematic review and meta-analysis of randomised controlled trials published before August 2020.
The review process involved:
- Searching multiple scientific databases, including PubMed, Medline, Scopus, Web of Science, Google Scholar, and the Cochrane Library
- Including only human randomised controlled trials that reported lipid outcomes
- Pooling results across studies using statistical models to calculate overall effects
What they found
A total of 38 randomised controlled trials were included in the analysis, involving 7605 participants and 41 treatment arms.
When results were combined across studies:
- Chromium supplementation was associated with a statistically significant reduction in total cholesterol
What it means according to the study
The authors concluded that chromium supplementation is associated with reduced total cholesterol levels when data from human trials are pooled.
Study: Chromium exposure and incidence of metabolic syndrome among American young adults over a 23-year follow-up: the CARDIA Trace Element Study
What the study was about
The CARDIA Study is a longitudinal investigation of CVD risk factors in 5,115 men and women aged 18 to 30 years. The researchers investigated whether levels of chromium in the body are linked to the future development of Metabolic Syndrome, a cluster of risk factors (high blood pressure, high blood sugar, abnormal lipids, excess waist fat) that increase the risk of heart disease and type 2 diabetes.
The study looked at the chromium levels of the participants over a period of 23 years. Chromium was investigated to give insight on the likelihood of Metabolic Syndrome in the future using clinical criteria (NCEP‑ATP III), based on measures like waist circumference, blood pressure, fasting glucose, triglycerides, and HDL cholesterol.
How the study was conducted
Chromium levels were measured in toenail clippings collected at the start. Toenails are considered a marker of longer‑term exposure to chromium from diet and environment.
Levels of chromium gave insight on the likelihood of Metabolic Syndrome in the future using clinical criteria (NCEP‑ATP III), based on measures like waist circumference, blood pressure, fasting glucose, triglycerides, and HDL cholesterol.
The team used statistical hazard models to estimate whether higher chromium levels were associated with lower incidence of Metabolic Syndrome, adjusting for key variables.
What they found
Individuals with higher toenail chromium levels at baseline had a lower long‑term risk of developing Metabolic Syndrome over 23 years.
Participants with the highest chromium levels had about a 20% lower risk of developing Metabolic Syndrome compared to those with the lowest levels, even after accounting for other factors. This protective effect appeared to be largely due to healthier blood lipid profiles, with higher chromium associated with lower triglycerides and higher HDL cholesterol
Why this matters
Metabolic Syndrome is a major public health issue because it increases risk for cardiovascular disease and type 2 diabetes.
This study provides some of the first long‑term prospective evidence in humans that higher chromium exposure (as reflected in toenail levels) may be linked to lower risk of developing Metabolic Syndrome, particularly through healthier lipid levels.
Recognising potential nutritional or environmental factors (like chromium) that influence metabolic risk could guide future preventive strategies and deeper research into biological mechanisms.
